Correlation Engine 2.0
Clear Search sequence regions


  • ag group (2)
  • blood (1)
  • cancer (2)
  • control group (2)
  • diagnosis (4)
  • donors (3)
  • gastric cancer (10)
  • gastritis (4)
  • humans (1)
  • mass (1)
  • patients (6)
  • pepsinogen (8)
  • pepsinogen i (4)
  • PGII (2)
  • serum (4)
  • stomach neoplasms (1)
  • Sizes of these terms reflect their relevance to your search.

    To compare the levels of serum pepsinogen (PG) in patients with gastric cancer (GC), patients with atrophic gastritis (AG), and healthy donors. Also, we explored the clinical value of PG detection for the diagnosis and treatment of GC. The PG level in peripheral blood from patients and heathy donors was determined using an Abbott automatic chemiluminescence instrument. The study included 117 patients with GC confirmed by gastroscopy and histopathology, of whom 13 patients had cancer at stage I, 47 at stage II, 41 at stage III, and 16 at stage IV. The AG group included 122 patients, and the control group had 120 healthy donors. The relationship between serum PG levels and the occurrence and development of GC, as well as the evaluation of the clinical value of diagnostic tests based on serum PG detection, were investigated by receiver operating characteristic (ROC) curve analyses. Pepsinogen I (PGI) levels gradually decreased from the control group, the AG group, and the GC group. PGI exhibited high diagnostic value for GC (area under the curve [AUC], 0.834; cutoff, 51.2 ng/mL, sensitivity, 81.7%; specificity, 68.4%), PGII (AUC, 0.587; cutoff value, 13.05 ng/mL; sensitivity, 65.8%; specificity, 53.8%), and PGR (AUC, 0.752; cutoff, 5.65; sensitivity, 54.2%; specificity, 87.2%). The occurrence of GC was negatively correlated with serum levels of PGI (B = -0.054; OR = 0.947; 95% confidence interval [CI], 0.925-0.970; P <.001) and PGR (B = -0.420; OR = 0.657; 95% CI, 0.499-0.864; P = .003). The combined detection of PGI, PGII, and PGR has important clinical value for the screening, prevention, and diagnosis of GC and could allow for earlier detection, diagnosis, and treatment of GC. © American Society for Clinical Pathology, 2021. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

    Citation

    Xiao-Lei Han, Chang-Lin Yi, Jin-Dan Ma, Yanhong He, La-Mei Wu, Yun-Feng Wang, Hui-Jian Yang, Dong-Yu Liang, Jin-Fang Shi. Clinical Value of Pepsinogen in the Screening, Prevention, and Diagnosis of Gastric Cancer. Laboratory medicine. 2022 Jan 06;53(1):71-77

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 34508270

    View Full Text